LifeLiver

HLB Cell, formerly known as LifeLiver Co. Ltd., is a biotechnology company specializing in regenerative medicine and advanced therapeutic solutions for liver disease. Its primary innovation is LifeLiver®, a bioartificial liver support system that functions as a sophisticated combination therapeutic, integrating cell therapy with a medical device. This system utilizes high-functioning hepatocyte spheroids within a bioreactor to detoxify blood and support critical liver functions, effectively acting as an external organ.

The company was founded as Lifeliver Co. Ltd. in 2009, established through the comprehensive transfer of research and development assets from Lifecord Inc., concurrently acquired by HLB. This formation was driven by the urgent need for temporary liver function support for patients experiencing acute or acute-on-chronic liver failure. The initial focus involved developing a system to bridge patients to liver transplantation, a significant challenge for those with deteriorating liver conditions.

LifeLiver® targets patients in critical need of liver transplantation, offering vital support to those with severe liver failure. The company’s long-term vision, as HLB Cell, is to significantly improve human health outcomes by developing next-generation medical devices and regenerative medicinal products. This is achieved by continuously advancing innovative platform technologies to overcome current limitations in tissue engineering and regenerative medicine.